These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 32051598)

  • 1. The promise and challenge of therapeutic genome editing.
    Doudna JA
    Nature; 2020 Feb; 578(7794):229-236. PubMed ID: 32051598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating Genetic Disorders Using State-Of-The-Art Technology.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Khan FA; Rehman K
    Curr Issues Mol Biol; 2018; 26():33-46. PubMed ID: 28879854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Germline Editing: Sense and Sensibility.
    Adashi EY; Cohen IG
    Trends Genet; 2020 May; 36(5):315-317. PubMed ID: 31982142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
    Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
    Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing.
    Hollister BM; Gatter MC; Abdallah KE; Armsby AJ; Buscetta AJ; Byeon YJJ; Cooper KE; Desine S; Persaud A; Ormond KE; Bonham VL
    CRISPR J; 2019 Dec; 2(6):441-449. PubMed ID: 31742431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
    Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
    Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
    [No Abstract]   [Full Text] [Related]  

  • 9. The Promise of CRISPR for Human Germline Editing and the Perils of "Playing God".
    Locke LG
    CRISPR J; 2020 Feb; 3(1):27-31. PubMed ID: 32091254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR in personalized medicine: Industry perspectives in gene editing.
    Hong A
    Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR and cardiovascular diseases.
    Musunuru K
    Cardiovasc Res; 2023 Mar; 119(1):79-93. PubMed ID: 35388882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
    [No Abstract]   [Full Text] [Related]  

  • 13. An Exclusive Interview With CRISPR.
    McConnell SC
    AMA J Ethics; 2019 Dec; 21(12):E1079-1088. PubMed ID: 31876473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ordo-Responsibility for Germline Gene Editing.
    Ranisch R; Rudolph T; Cremer HJ; Knoepffler N
    CRISPR J; 2020 Feb; 3(1):37-43. PubMed ID: 32091257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Crispr-Cas9 Gene Editing Revolution and the Its Ethical and Legal Challenges].
    Bellver Capella V
    Cuad Bioet; 2016; 27(90):223-39. PubMed ID: 27637196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding the noncoding genome via large-scale CRISPR screens.
    Shukla A; Huangfu D
    Curr Opin Genet Dev; 2018 Oct; 52():70-76. PubMed ID: 29913329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.